EZH2 and plasma cell myeloma: In this study, 17-AAG (Figure S3), an HSP90 inhibitor candidate in human clinical trials (multiple myeloma; phase 3), potentially exerted an inhibitory activity on EZH2, PAX5 and KHDRBS1 genes associated with the risk of developing metastatic phenotypes (Figure 8) by modulating gene expression (Figure S7).